Pfizer rated at outperform by Bear Stearns

Pfizer was rated at outperform with a $30 price target by Bear Stearns analyst John Boris. The company's first-quarter 2006 global revenues were $350 million below the analyst's estimate. Bear Stearns lowered its global 2006 Lipitor estimate by $500 million to $12.7 billion from $13.2 billion. With Pfizer on the offensive, three biotech acquisitions could be expected. Shares of the New York City pharmaceutical company were up 13 cents, or 0.52%, at $24.95 on volume of 24,950,100 shares versus the three-month running average of 27,474,100 shares. (NYSE: PFE)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.